Emerin is a nuclear membrane protein that interacts with lamin A/C at the nuclear envelope. Mutations in either emerin or lamin A/C cause Emery-Dreifuss muscular dystrophy (EDMD). The functions of emerin are poorly understood, but EDMD affects mainly skeletal and cardiac muscle. We used a high-stringency yeast two-hybrid method to screen a human heart cDNA library, with full-length emerin as bait. Four out of five candidate interactors identified were nuclear proteins: lamin A, splicing factor YT521-B, proteasome subunit PA28c and transcription factor vav-1. Specific binding between emerin and the functional C-terminal domain of YT521-B was confirmed by pull-down assays and biomolecular interaction analysis (BIAcore). Inhibition by emerin of YT521-B-dependent splice site selection in vivo suggests that the interaction is physiologically significant. A ÔbipartiteÕ binding site for YT521-B in emerin was identified using alanine substitution or disease-associated mutations in emerin. The transcription factor GCL (germ cell-less) has previously been shown to bind to the same site. The results are consistent with an emerging view that lamins and lamina-associated proteins, like emerin, have a regulatory role, as well as a structural role in the nucleus. YT521-B joins a growing list of candidates for a role in a gene expression model of the pathogenesis of EDMD.
The STA gene (Xq28) encodes a nuclear protein, emerin, and mutations in STA cause the X-linked recessive form of Emery-Dreifuss muscular dystrophy (X-EDMD) [1] . An autosomal dominant form of EDMD (AD-EDMD) is caused by mutations in the lamin A/C gene [2] and displays a phenotype similar to X-linked EDMD [3, 4] . Emerin and lamins colocalize at the nuclear rim [5, 6] . Emerin and lamins also coimmunoprecipitate [7] and a direct interaction between emerin and lamin A has been demonstrated [8, 9] . The LEM domain at the emerin N-terminus (amino acids is shared by other nuclear membrane proteins, such as LAP2b [10] and MAN1 [11] , and interacts with the DNAbinding protein, BAF [9] . Yeast two-hybrid studies have shown that the tail region of lamins A and C is responsible for binding emerin [12, 13] . The lamin A/C knockout mouse displays muscular dystrophy [14] , suggesting that EDMD is caused by functional defects in the lamin A/C-emerin complex (reviewed in [4] ).
Most mutations in the emerin gene lead to early stop codons or cause complete deletion of the gene [15, 16] . Missense mutations S54F and P183H/T, and a small deletion, DYEESY, also cause EDMD, though emerin is produced and is still able to localize to the nuclear membrane [7, 9, 17] . Understanding the molecular effects of these missense mutations is clearly important for understanding emerin function and the pathogenesis of EDMD. Recently, Lee et al. [9] located the lamin A binding region of emerin to amino acids 70-178 and showed that DYEESY within this region reduces lamin A binding. The Tsuchiya-Ö stlund sequence (amino acids 107-175 [18, 19] ), necessary for targeting emerin to the nuclear rim, lies within this lamin-binding region, consistent with evidence from the knockout mouse that lamin A/C is at least partially responsible for targeting emerin to the nuclear envelope [14] . Two missense mutations, S54F and P183H, did not affect binding to either lamin A or BAF [9] , suggesting that there may be additional emerin interactions, yet to be identified, involving these residues. A third missense mutation, Q133H, lies within the lamin-binding region but does not affect binding to lamin A [20] . This mutation also causes aberrant splicing of emerin mRNA, which may contribute to the phenotype [21] .
EDMD is predominantly a disease of cardiac and skeletal muscle and tendons, other tissues being unaffected [4] . The EDMD phenotype suggests that complexes between lamin A/C and emerin might have functions specific for muscle, potentially involving muscle-specific binding partners. Nesprin-1a, an integral membrane protein that localizes to the skeletal muscle nuclear membrane [22] , binds to lamin A and is a high-affinity binding partner for emerin [23] . We therefore used the yeast two-hybrid method to screen a human heart cDNA library for novel emerin binding partners. Our identification of an RNA-splicing protein named YT521-B [24, 25] , reported here, adds significantly to the functional range of proteins that interact with emerin.
Small disruptions of the normal balance of gene expression may lead to the slow degeneration of cardiac and skeletal muscle tissues associated with EDMD.
Materials and methods

Yeast two-hybrid screening
A yeast two-hybrid human heart cDNA library in plasmid pPC86 (Proquest; Invitrogen), containing the activating domain, was screened using the full-length coding sequence of emerin cDNA as ÔbaitÕ, in the binding domain plasmid, pDBLeu. The screen was performed in the MaV203 yeast strain according to the supplier's instructions. EmerinpDBLeu was introduced into the yeast strain, followed by the library plasmid DNA (sequential transformation). Approximately 10 6 yeast transformants were screened. The transformation mixture was plated out onto dropout plates lacking leucine, tryptophan and histidine (SC-L/ -T/-H) that had been supplemented with 25 mM 3-aminotriazole. HIS3-positive colonies were recloned and streaked onto dropout plates lacking leucine and tryptophan (SC-L/ -T). The yeast were replica-plated onto filter paper on nutrient-rich YPAD medium and tested for activation of the lacZ gene using the X-gal assay.
Plasmid DNA was isolated from lacZ-positive clones and used to transform Escherichia coli DH5a for plasmid propagation and sequencing (Cytomyx, Cambridge, UK). BLAST (www.ncbi.nlm.nih.gov/BLAST) was used to search nucleotide databases for sequence similarities. The size of each interactor cDNA in pPC86 was determined by digestion with SalI and NotI. The isolated plasmid (interactor in pPC86) was reintroduced into yeast carrying emerin-pDBLeu and retested for activation of the lacZ, HIS3 and URA3 reporter genes. HIS3 activation was assessed by growth on SC-L/-T/-H + 25 mM 3-aminotriazole dropout plates and URA3 by growth or lack of growth on SC-L/-T/-U or SC-L/-T + 5-fluoro-orotic acid dropout plates, respectively. Candidate partners were also tested in pDBLeu alone to control for auto-activation.
Protein expression and immunoprecipitation
Candidate interactor cDNAs in pPC86 were excised with SalI and NotI, filled and cloned blunt ended into EcoRVdigested pET32a (Novagen). This vector adds an N-terminal thioredoxin sequence to improve recombinant protein solubility, as well as a His-tag. 35 S-methionine-labelled interactor proteins were expressed from the T7 promoter using the TNT Quick Coupled Transcription-Translation System (Promega) according to the manufacturer's protocol. The fragments corresponding to PA28c and YT521-B included 966 and 568 bp, respectively, up to the natural stop codon. The predicted sizes of the recombinant proteins were 57 kDa for PA28c and 42 kDa for YT521-B, including amino acids encoded by the vector. In addition to protein fragments from yeast two-hybrid cDNAs, 35 S-methioninelabelled full-length lamin A was produced from pcDNA4 [26] and PA28c from pET16b (a generous gift from S. Wilk, Mount Sinai School of Medicine, New York). Full-length PA28c (31 kDa) served as an essential control because the recombinant protein recovered in our two-hybrid screen included N-terminal residues encoded by the 5¢-untranslated region, which are not normally expressed and might be responsible for nonphysiological binding to emerin.
The nucleoplasmic domain (residues 1-222) of wild-type and mutant emerins were expressed in E. coli BL21 (DE3)pLysS. The C-terminal 32 residues, which include the hydrophobic transmembrane span, were removed to avoid nonspecific binding to a region of emerin that is inaccessible to soluble proteins. This shorter form of emerin in pET11c was also used to generate mutant proteins S54F and P183H [9] . Log-phase cells were induced with isopropyl thio-b-D-galactoside at 37°C for 3-4 h and washed once with TNE buffer (50 mM Tris/HCl, 150 mM NaCl, 10 mM EDTA pH 7). Emerin-containing inclusion bodies were washed twice with TNE and extracted by sonication with 8 M urea in NaCl/P i . Two control recombinant proteins, full-length fukutin and a fragment of neuronal apoptosis inhibitory protein (NAIP; residues 112-476), were expressed and extracted under the same conditions. The amounts of emerin and control proteins were balanced, based on densitometry of Coomassie blue stained SDS/PAGE gels (data not shown). The beads were washed thoroughly three times with 300 lL NaCl/P i containing 0.1% Triton X-100. The protein mixture was added to the beads, made up to 80 lL in IP buffer and incubated for 2 h at 4°C. The beads were washed with IP buffer and eluted with SDS sample buffer [62.5 mM Tris/HCl pH 6.8, 2% SDS (w/v), 5% 2-mercaptoethanol, 2% glycerol, 0.05 mgAEmL )1 Bromophenol blue; 30 lL). An aliquot (10 lL) was analysed by SDS/PAGE (12.5% acrylamide), followed by fixing and drying, and exposed to X-ray film for 24-48 h.
Microtiter binding assays
Microtiter well-binding assays were carried out essentially as described [27, 28] . To test for YT521-B binding to our collection of emerin mutants, 35 S-labelled YT521-B protein was synthesized in coupled transcription/translation extracts, and a subsaturating amount (40 nM) of 35 S-YT521-B was added to each well; wells contained 10 pmol emerin plus BSA to block nonspecific binding sites. Wells were not allowed to dry at any time during these assays. Negative control wells contained BSA only. Wells were washed, and bound 35 S-labelled proteins were extracted with 5% SDS and counted in a scintillation counter. Emerin mutants were described elsewhere [9, 28] , but are summarized here; each mutant comprised a small cluster of alanine substitutions and was numbered according to its most N-terminal mutated residue: m24 (24-GPVV to AAAA), m34 (34-YEKK to AAAA), m45A (45-RRR to AAA), m45E (45-RRR to EEE), m70 (70-DADMYD to AAAMAD), m76 (76-LPKKEDAL to APAKADAA), m112 (112-GPS RAVRQSVT to AASRAVAAAVA), m122 (122-TS to AA), m133 (133-Q to H), m145 (145-EE to AA), m151 (151-ER to AA), m161 (161-YQS to AAA), m164 (164-ITHYRPV to AAHARPA), m175 (175-SSL to AAA), m179 (179-LS to AA), m192 (192-SSSSS to ASAAA), m196 (196-SS to AA), m198 (198-SSWLTR to AAAAAA), m206 (206-IRPE to AAPA), m207 (207-RP to AA), m214 (214-GAGL to AAGA). Mutant m40 (40-E to K) is described here for the first time.
Biomolecular interaction analysis (BIA)
The BIAcore biosensor measures changes in surface plasmon resonance angle produced by changes in total mass at the surface of a sensor chip. Resonance units (RU) are proportional to the mass on the chip, so that real-time binding can be followed and quantified. Rabbit antimouse IgG was covalently bound to a dextran sensor chip by amino-coupling according to the manufacturer's instructions (BIAcore AB, Stevenage, UK). The operating flowrate of the BIAcore-X apparatus was 20 lLAEmin )1 using HBS (20 mM Hepes pH 7.5, 150 mM NaCl, 3.4 mM EDTA, 0.005% P20 surfactant) as the running buffer. This buffer was also used to dilute all proteins to 20 lgAEmL )1 just before use. Recombinant YT521-B (the two-hybrid fragment) and PA28c proteins were extracted from E. coli with TNE buffer, as described above.
In vivo splicing assay
This was performed as described previously [29] . Briefly, 1 lg of the CD44 v5 minigene [29] was transfected into 3 · 10 5 HEK293 cells in the presence of cDNAs encoding EGFP-YT521-B [25] or emerin. RNA was isolated using RNeasy columns (Qiagen). 1 lg total RNA was reverse transcribed and amplified by PCR as described [29] .
Results
Candidate binding partners for emerin from a yeast two-hybrid library
The Proquest yeast two-hybrid system minimizes nonspecific interactions by using low copy number plasmids and by having four different phenotype requirements for a positive score. In general, fewer interactors are pulled out of Proquest libraries than systems using high-copy-number plasmids (e.g. Clontech Matchmaker). We used full-length emerin as bait, including the hydrophobic transmembrane sequence. To control for the presence of the transmembrane domain, we subsequently checked all interactors biochemically for binding to the N-terminal nucleoplasmic domain only (residues 1-222). Five potential binding partners were identified in the initial two-hybrid screen: lamin A, PA28c, YT521-B, lipoprotein lipase and the Vav1 oncogene (Fig. 1) . The mRNA map for each putative emerin-binding protein is shown in Fig. 2 . Control experiments showed that these interactors did not auto-activate reporter genes when re-introduced into yeast without emerin, but did again activate reporter genes when re-cotransformed with the emerin bait (Fig. 1) .
Finding lamin A, a known emerin-binding protein, showed that the two-hybrid screen worked well. Furthermore, the lamin cDNA recovered in our two-hybrid screen included the C-terminal globular ÔtailÕ region of lamin A previously suggested to bind emerin [12, 13] . Three of our novel interactors, Vav1, PA28c and YT521-B, are known to be nuclear proteins, consistent with potential binding to emerin. Vav1, the nuclear proto-oncogene was not pursued further in this study because it is expressed mainly in haematopoietic cells [30] , which are not affected by EDMD. The last interactor, lipoprotein lipase, was not studied further, as it is secreted by several cell types and has no known nuclear function [31] . For this report, we To compare interaction strengths, the same six interactors (right) are compared to five strains (left) that express pairs of proteins with known interaction affinities (provided with Proquest system). Anticlockwise, these controls were (A) negative control strain, (B) human RB and E2F1 [43] , (C) Drosophila melanogaster DP and E2F [44] , (D) rat c-fos and mouse c-jun [45] and (E) positive control (intact GAL4). Yeast marked ÔAD + Emerin-BDÕ show that emerin alone does not autoactivate the lacZ reporter gene.
focussed on two novel partner candidates, PA28c and YT521-B.
The PA28c fragment included 74 extra residues at the N terminus that derived from the 5¢-untranslated region, and are presumably never synthesized in vivo. To determine if its interaction with emerin was due to these Ônon-PA28cÕ residues, all subsequent studies were performed using both the longer two-hybrid polypeptide and wildtype PA28c. Full-length YT521-B was not available due to problems expressing this protein in bacteria, so we studied the function of the C-terminal fragment of YT521-B, which was sufficient to bind emerin in the yeast two-hybrid assay.
Biochemical evidence for emerin interaction with YT521-B
For immunoprecipitation studies, each purified recombinant protein (wild-type emerin residues 1-222, mutant emerins or control proteins) was preincubated with the 35 S-labelled ÔinteractorÕ protein, and then captured onto magnetic beads using the appropriate monoclonal antibodies against emerin or the control proteins. Approximately equal concentrations of each protein (± 10%) were present in each reaction, as estimated from densitometry of Coomassie-stained gels. Our negative control proteins were full-length fukutin and a recombinant fragment of NAIP expressed and extracted from bacteria in the same way as the emerins.
These pull-down assays showed that lamin A, PA28c and the YT521-B protein all bound to wild-type emerin (Fig. 3A) . The efficiency of capture was plotted as a The arrows denote the insert sequences of the clones from the human heart library. The PA28c cDNA was not sequenced in its entirety and the dotted arrow shown denotes the estimated length of the insert. The lengths of the inserts were estimated by restriction digestion with SalI and NotI. percentage of the input 35 S-probe (Fig. 3B,C) . Binding of YT521-B to emerin was most efficient, with 5.8% of the input probe captured by emerin, compared to 2.2% of the input lamin A (Fig. 3B) . Binding to YT521-B was specific, because an average of 8.5% of YT521-B input was captured by emerins compared with an average 0.6% captured by negative control proteins fukutin or NAIP (Fig. 3B) . The corresponding numbers for lamin A were an average 2.6% of input captured by emerins compared with 0.8% by control proteins. In contrast, wild-type PA28c and twohybrid encoded PA28c bound significantly to the negative control proteins, with an average 3.7% of input probes captured by negative control proteins, compared to 3.3% captured by emerins (Fig. 3C) . We concluded that the twohybrid interaction between emerin and PA28c was nonspecific. In summary, these biochemical results eliminated PA28c as a candidate, and independently verified YT521-B as a bona fide emerin-binding protein.
We also tested two emerin missense mutations, S54F and P183H, for possible disruption of emerin binding to YT521-B (Fig. 3) . Neither mutation disrupted emerin binding to lamin A, but the P183H mutation enhanced emerin binding to lamin A, consistent with earlier reports [9] . Neither disease-causing mutation reduced emerin binding to YT521-B. However, similar to its effects on lamin A [9] , the P183H mutation increased emerin binding to YT521-B (Fig. 3) . This enhanced binding of emerin mutant P183H was reproduced in multiple immunoprecipitation experiments and with different mutant emerin preparations, but its significance remains unclear (see Discussion).
The BIAcore biosensor detects protein-protein interactions in real time using surface plasmon resonance. Molecules binding or dissociating from the sensor chip are monitored by a change in the surface plasmon resonance response (RU) proportional to the mass on the chip [8] . An emerin mAb (MANEM1) was captured onto a rabbit antimouse sensor chip. YT521-B or PA28c recombinant proteins were injected over the sensor chip to control for nonspecific binding of these proteins; the baseline was unchanged and thus no binding was detected (Fig. 4) . Emerin was then injected and captured onto the same chip ( Fig. 4 ; + 504 RU), and subsequent addition of YT521-B gave a positive binding signal ( Fig. 4 ; + 180 RU). This result provided the third line of evidence supporting an interaction between emerin and YT521-B. No signal was seen for PA28c ()20 RU), confirming its lack of binding to emerin in solution (data not shown).
Mapping residues in emerin required to bind YT521-B YT521-B was tested for binding to a collection of emerin mutants bearing clusters of alanine-substitution mutations, which were used previously to map the binding sites for BAF, lamin A and GCL [9, 28] . Figure 5A . This binding site is bipartite, which may imply some folding of emerin around its lamin-binding domain. Antibody studies have also suggested folding within the lamin-binding domain of emerin [32] .
Emerin influences YT521-B-dependent splice sites in vivo YT521-B has been shown to influence splice site selection in cotransfection experiments [25] . To determine whether emerin has a similar effect on splice site selection, we cotransfected HEK293 cells with expression constructs encoding emerin and a CD44 reporter gene. Fig. 6A shows that transfecting emerin alone had no effect on exon 5 inclusion, in contrast with transfection with YT521-B alone, which reduced exon 5 inclusion (Fig. 6B) as expected [25] . Cells transfected with 1 lg YT521-B had inclusion of exon 5 reduced significantly (P ¼ 0.006; t-test) from 34% to 17% (Fig. 6B) . To determine if emerin influenced YT521-B, we cotransfected cells with both proteins and tested their influence on exon 5 of the CD44 reporter gene [33] . If emerin was also present, the effect of YT521-B on splicing was partially reversed from 17% to 24% (Fig. 6B) . Both emerin expression (Fig. 6C ) and its effect on splicing (Fig. 6B) were dose-dependent and there was a significant difference in splicing (P ¼ 0.008; t-test) between experiments with no detectable emerin expression (Fig. 6B, lanes 2  and 3) and those in which emerin was present (Fig. 6B,  lanes 4-6) . This is the first indication that full length YT521-B and emerin interact in vivo. Since emerin itself does not affect splice site selection, this effect is most likely mediated by its binding to YT521-B.
Discussion
This work has identified a novel emerin-binding protein, the ubiquitously expressed nuclear splicing-associated factor YT521-B [25] . The binding of emerin to YT521-B was confirmed by three independent biochemical methods (pull-downs, BIAcore and microtiter binding assays). The interacting region of YT521-B comprises part of a prolinerich domain that lacks secondary structure, plus the intact C-terminal ÔGlu-ArgÕ domain (ÔR-D/EÕ domain), which is required for binding to several known RNA splicing factors including Sam68 and htra2-b1. Binding between Glu-Arg domains and splicing factors is regulated by the Src family kinase, p59
fyn [25] . Our results suggest that fulllength YT521-B and emerin interact in vivo, and that this interaction is physiologically significant as emerin influenced YT521-B-dependent splicing in vivo. The binding regions on emerin for YT521-B also interact with a transcription factor, GCL, and binding of BAF to the adjacent LEM domain of emerin interferes with this GCL interaction [28] . This raises the possibility that interactions of this particular binding region of emerin are dynamic in vivo and occur only under specific circumstances. The fact that emerin and BAF only colocalize at specific stages of the cell cycle [34] supports this concept of dynamic interactions.
In our immunoprecipitation assays, emerin pulled down a higher proportion of input YT521-B than any other protein tested, including lamin A, suggesting that its binding is relatively tight in vitro. Binding to YT521-B was not disrupted by either of two emerin missense mutations that cause EDMD. However we are intrigued by the possibility that the P183H mutation might alter emerin dynamics by binding too tightly to both lamin A [9] and splicing factor YT521-B (Fig. 3B) . It is interesting to note that myotonic dystrophies (DM1 and DM2) are now thought to be caused, at least in part, by defects in RNA splicing that result from the accumulation in the nucleus of expanded CUG repeats in nuclear RNA [35] . Myotonic dystrophies are multisystem disorders that share two major clinical features with EDMD: cardiac conduction system defects and skeletal muscle wasting. Two additional features of myotonic dystrophy, myotonia and insulin resistance, have been directly linked to defective alternative splicing of mRNAs encoding a muscle chloride channel [36, 37] and insulin receptor [38] , respectively. In the heart, splicing of the mRNA encoding cardiac troponin-T is also altered in DM1 [39] . Thus, it is possible that many, if not all, clinical features of myotonic dystrophy are caused by defects in mRNA splicing.
YT521-B has been shown to modulate alternative splice site selection in vivo [25] ; this activity requires the C-terminal Glu-Arg domain that our evidence suggests can also interact with emerin. If the normal functions of YT521-B are somehow regulated by interactions with emerin or the emerin-lamin A/C complex, some of the cardiac and skeletal muscle symptoms of EDMD may result from inappropriate splicing of tissue-specific mRNAs. This could explain how changes in widely expressed proteins like YT521-B and emerin might produce the tissue-specific effects in EDMD [4] . Although the functional effects of emerin on YT521-B may appear modest, it must be remembered that effects of complete absence of emerin in X-EDMD are also quite modest, with clinical features appearing many years after birth, and we would not expect lack of emerin to have any drastic effect on ÔhousekeepingÕ functions [28] . Splicing defects are often associated with lateonset disease or predisposition to disease [40] .
Emerin binding to YT521-B might sequester or inactivate YT521-B, as suggested by our in vivo splicing results. Alternatively, the emerin-lamin A/C complex might help to organize transcription factors, splicing factors and chromatin to ensure that specific RNA transcripts are correctly spliced. Alternative splicing can regulate gene expression directly by changing the polypeptides encoded by primary RNA transcripts. However, transcription factors are themselves the products of alternative splicing, and defects in splice site selection may have downstream indirect effects on gene expression due to inappropriately expressed transcription factors (reviewed in [25] ). The adipocyte differentiation and transcription factor known as Ôsterol response element binding protein 1Õ (SREBP1), binds to lamin A and this binding is affected by a lamin A/C mutation that causes lipodystrophy [41] . The retinoblastoma transcription factor, Rb, binds to the emerin-related LEM domain protein, LAP2a [42] . Haraguchi et al. (personal communication) have shown that Btf, a transcriptional repressor that is highly expressed in muscle, interacts with emerin. It is impossible to say at present which of the currently known emerin-binding factors are involved in the pathogenesis of EDMD. However, the hypothesis that absence or disruption of the emerin-lamin A/C complex has downstream effects on gene expression that lead to specific degeneration of skeletal and cardiac muscle now deserves serious consideration.
